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CORRELATION OF MULTIPARAMETRIC MRI (MPMRI) WITH PSA IN 
ASSESSMENT OF RESPONSE TO COMBINED HDR PROSTATE 
BRACHYTHERAPY AND EXTERNAL BEAM RADIOTHERAPY FOR 
UPPER TIER INTERMEDIATE AND HIGH-RISK PROSTATE CANCER 
Juanita Crook1, Francois Bachand1, Sylia Chang2, Deidre 
Batchelar1, Matt Schmid1 
1University of British Columbia, Kelowna, BC 
2University of British Columbia, Vancouver, BC  
Purpose: mpMRI has been demonstrated to be very useful for 
staging and surveillance of localized prostate cancer. The PiRads 
system has been developed for scoring the malignant probability 
of lesions. We identified the dominant intra-prostatic lesion (DIL) 
on mpMRI for intermediate- and high-risk prostate cancer before 
and 15 months after radiation to determine if the PiRads system 
could be useful in assessing the radiologic response to treatment. 
Methods and Materials: From August 2012 to July 2013, 26 
patients with predominantly unilateral disease consented to a 
University Ethics-approved Phase 2 study of selective dose 
escalation. HDR brachytherapy was performed in weeks 1 and 3 
of treatment, each delivering one fraction of 10 Gy to the whole 
prostate. External beam consisted of 46 Gy/23 fractions starting 
within one week after the first HDR fraction. Pre-treatment T2 
FSE images were obtained using 1.5T endorectal MRI in 
transverse, sagittal and coronal planes followed by Dynamic 
Contrast Enhancement after injection of gadolinium. Apparent 
Diffusion Coefficient maps were calculated. Following image 
registration, the DIL was transposed to the intra-operative TRUS 
with source-delivery catheters in place for the purpose of a 25% 
escalation in dose. At median 15.6 mo (12-18.6) mp MRI was 
repeated in the 16 patients who did not receive ADT. 
Results: Twenty-five out of 26 patients initially had a visible DIL. 
Mean pre-treatment PiRads score was 4.1 (range 3-5 for region 
of biopsy-proven disease). Coverage of the DIL was excellent 
with a median of 97% receiving the planned escalation of 25%. 
Mean PiRads score in follow up mpMRI in 16 patients at a median 
of 15 months post-treatment was 2.7. Median PSA was 0.2. Only 
two MRI’s still received a PiRads score of 4 and PSA for these two 
patients was 1.4 and 1.2; all others were < 0.5 ng/ml. Current 
PSA is 1.1 and 1.02 for these two patients and biopsies show 
scattered foci of residual tumour with marked RT effect. 
Conclusions: mpMRI using the PiRads classification may be 
adjunctive to PSA to assess response to radiation. Optimal timing 
and correlation with biopsy findings needs to be determined in a 
larger population. 
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ACUTE AND LATE TOXICITY IN HIGH-RISK PROSTATE CANCER 
PATIENTS TREATED WITH ANDROGEN SUPPRESSION AND 
HYPOFRACTIONATED RADIOTHERAPY (HYPORT) TO THE 
PROSTATE AND PELVIC NODES  
Sergio Faria1, Mariana Petrucelli2, Fabio Cury1, Marie Duclos1, 
Luis Souhami1 
1McGill University Health Centre, Montreal, QC 
2Radiation Oncology, Rio de Janeiro, Brazil 
Purpose: Moderate HypoRT is an acceptable option in the 
curative treatment of prostate cancer. Among different 
fractionation regimens, the dose of 60 Gy in 20 fractions 
was used in prospective randomized trials (PROFIT, CHiiP), 
mainly for low and intermediate-risk patients where the PTV 
is only the prostate(+/- seminal vesicle(SV) but not the 
pelvic nodes. We report here the acute and late toxicity in 
high-risk prostate cancer patients treated with androgen 
suppression and HypoRT to the prostate and pelvic nodes with 
doses of 60 Gy to prostate and 44 Gy to the pelvic nodes 
given in 20 fractions with a simultaneous integrated boost.  
Methods and Materials: Localized high-risk prostate 
cancer patients (T3, or PSA>20ng/ml, or GS >8) were 
treated with androgen suppression (6-24 months) started 2-3 
months before HypoRT. Radiotherapy was delivered using IMRT 
with daily IGRT. Constraints for organs at risk were the 
same of RTOG-0126 
corrected with the linear-quadratic model (α/β=3Gy). A dose of 
44 Gy (2.2 Gy/fraction) was delivered to the pelvic nodes and 60 
Gy (3 Gy/fraction) to the prostate (+/-SV) with a concomitant 
boost in 20 fractions (4 weeks). Cone beam CT was used daily to 
guide the treatment accuracy. Acute and late toxicities were 
assessed prospectively and scored using the National Cancer 
Institute Common Terminology Criteria for Adverse Events, 
version3.0. Biochemical failure was determined using the 
Phoenix definition. 
Results: 105 patients treated between September/2010 and 
November/2013 were reviewed. Median age, median initial PSA 
and T stage were 72 years (52-84), PSA=14(1.8-108), T1c = 36 and 
T3= 22 patients. Median follow up is 35 months (12-61). Acute GI 
toxicity (%) was as follows: Grade 0 = 38, Grade 1 = 45, Grade 2 
= 16 and Grade 3 = 1. Acute GU toxicity(%): Grade 0 = 32, Grade 
1 = 50, Grade 2 = 14 and Grade 3 = 3. The worst late GI toxicity(%) 
was, as follows: Grade 0 = 74 Grade 1 = 19, Grade 2/3 = 7. The 
worst late GU toxicity(%) was: Grade 0 = 77, Grade 1 = 15, Grade 
2/3 = 8. There was no Grade>3 toxicity. At the last follow-up the 
incidences of grade 2  late GU and GI toxicity were 5% and 3%, 
respectively (no residual grade >2 toxicity). At this limited 
follow-up, 13 patients developed biochemical failure at a median 
time of 27 months with 8 of them showing evidence of metastatic 
disease. Three patients died so far, and one from prostate 
cancer. 
Conclusion: Androgen suppression with moderate HypoRT IMRT 
and IGRT to the prostate (60Gy) and pelvic nodes (44Gy) 
delivered with simultaneous integrated boost in 4 weeks (20 
fractions) is feasible and well tolerated. Further follow-up is 
needed to establish long-term PSA control rates and survival 
outcomes.  
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A POPULATION-BASED STUDY OF RADIATION THERAPY REFERRAL 
AND TREATMENT PRACTICES POST-PROSTATECTOMY OVER A 
DECADE (2003-2012) 
Chunzi Jenny Jin1, Timothy Hanna2, Earl Cook3, Qun Miao2, 
Michael Brundage2 
1Harvard School of Public Health, Boston, MA 
2Queen’s University, Kingston, ON 
3Harvard T.H. Chan School of Public Health, Boston, MA 
Purpose: Adjuvant radiotherapy (ART) post-radical 
prostatectomy (RP) has been shown to benefit patients with 
pathologic T3 or margin-positive prostate cancer. Early salvage 
radiotherapy (SRT) is commonly practiced, but it remains unclear 
if SRT confers equivalent outcomes to ART. Recent Ontario 
Practice Guidelines recommend referral to radiation oncology 
(RO) within six months of RP to discuss ART and SRT. Our 
objectives were to describe patterns of care over time to (1) 
assess post-RP referral patterns to RO; (2) describe ART and SRT 
utilization; and (3) compare time trends before and after seminal 
trials and guidelines were published, and in doing so, provide 
indications of access to quality care.  
Methods and Materials: This was a retrospective cohort study. 
Electronic clinic visit and RT treatment records were linked to 
the population-based Ontario Cancer Registry. The study 
population included all prostate cancer cases treated with RP in 
Ontario January 1, 2003 - November 30, 2012. ART was defined 
as curative RT within six months of RP, and SRT was 6 - 24 months 
post-RP. Changes in RO referral and RT rates over time were 
statistically analyzed using the Cochran-Mantel-Haenszel Chi-
Square test.  
Results: Over the study period, 30,447 prostate cancer patients 
received RP and 15.2% saw an RO within six months of RP. This 
proportion doubled between 2003 and 2012 (from 10.7% in 2003-
2004 to 21.7% in 2011-2012, p < 0.001 for trend). The annual 
percentage change was largest 2009-2011 (3.4% increase). In 
comparison, the proportion seen within 24 months of RP 
remained stable at 32.3% ± 1.4%. Amongst the 4,641 patients 
seen by an RO within 6 months of RP for consideration of ART or 
SRT, the proportion receiving ART remained relatively constant 
at 51.0% ± 3.0%. Commensurate with RO referral trends, there 
S22                                                                                     CARO 2016 
_________________________________________________________________________________________________________ 
was a doubling in ART rates amongst all RP cases, ranging from 
5.4% in 2003-2004 to 11.0% in 2011-2012 (p < 0.001), compared 
to relatively stable SRT rates of 8.5% ± 0.2% (7.9% in 2003-2004, 
8.9% in 2010-2011). Consequently, the total proportion receiving 
RT within 24 months of RP increased from 14.1% in 2003-2004 to 
19.8% in 2010-2011 (p < 0.0001). 
Conclusions: There was an increase in access to early RO referral 
post-RP and in ART utilization in Ontario from 2003 to 2012, 
following publication of key clinical trials and guidelines. 
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SURVEYING THE LANDSCAPE: CONGRUENCE OF A PROVINCIAL 
CANCER AGENCY PATIENT EDUCATION PROGRAM WITH NATIONAL 
STANDARDS 
Paris-Ann Ingledew, Joy Bunsko, Angela Bedard, Pamela Dent, 
Lynne Ferrier, Anne Hughes, Brenda Ross, Amanda Bolderston 
British Columbia Cancer Agency, Surrey, BC 
Purpose: Patient education interventions are recognized as an 
essential component of cancer treatment. They improve 
treatment compliance and decrease anxiety, stress and health 
care costs. The Canadian Partnership Against Cancer (CPAC) 
Cancer Patient Education Framework (CEF) recommended that 
each cancer organization should have an embedded 
comprehensive cancer patient education program. The CEF 
defined the essential components of patient education as 
assessment of learning needs, development of a learning plans, 
defined delivery methods and evaluation. Unfortunately, many 
Canadian cancer centres lack identifiable patient education 
programs, program leadership, and financial resources. 
In a recent survey, of a provincially coordinated cancer care 
program, patients identified significant gaps in patient education 
initiatives. We sought to undertake a provincial review of our 
current programs, from the perspective of health care providers. 
By using an established conceptual model from the CEF for 
interpretation of the results we hoped to identify both strengths 
and gaps. 
Methods and Materials: Between 2013-2015 a multi-phased 
project was conducted. First, an environmental scan was 
undertaken to describe current practices in our six provincial 
cancer centres, associated provincial health agencies and 
national cancer centres. In the second phase, three focus groups 
were held. The CEF provided the scaffold for interview question 
development. In the final phase, themes emerging from the focus 
groups guided the development and administration of an 
electronic survey distributed provincially to 254 health care 
providers (HCP). 
Results: The environmental scan confirmed that in comparison 
to other local, provincial and national health care agencies, 
there are significant gaps in the existing provincial patient 
education program. The focus groups identified three major 
themes of logistical (e.g. methods of educational delivery), 
intrinsic (e.g. provider knowledge) and extrinsic (e.g. physical 
space) factors that impacted educational delivery. With respect 
to the electronic survey, 190/254 HCPs completed it. While 88% 
of respondents felt teaching was an essential activity, 66% lacked 
knowledge in effective education techniques. Seventy-two 
percent of respondents always assessed their patient’s capacity 
for processing information yet only 17% developed individual 
patient learning plans. 55% of HCPs felt they lacked time and 
resources. Only 8% of HCPs reported their teaching or programs 
were evaluated routinely. 
Conclusions: By applying the CEF to analyze a current provincial 
cancer program, strengths and gaps were highlighted. While 
many HCPs view patient education as critical to clinical care 
activities, there are deficiencies in assessment of patient needs, 
development of learning plans, barriers to delivery and little 
evaluation of outcomes. These results will help strengthen 
current provincial delivery methods and may be informative for 
other cancer centres. 
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DEVELOPMENT OF A QUALITY AND SAFETY COMPETENCY 
CURRICULUM FOR RADIATION ONCOLOGY RESIDENCY: AN 
INTERNATIONAL DELPHI STUDY  
Jenna Adleman1, Caitlin Gillan1, Amanda Caissie2, Carol-Anne 
Davis2, Brian Liszewski3, Andrea McNiven1, Meredith Giuliani1 
1University of Toronto, Toronto, ON  
2Dalhousie University, Halifax, NS 
3Odette Cancer Centre, Toronto, ON  
Purpose: The purpose of this study was to develop an entry-to-
practice quality and safety competency profile for radiation 
oncology residents to guide training in this area. 
Methods and Materials: A list of 1211 potential quality and 
safety competency items was compiled from a range of 
international sources, including quality-related course 
objectives, competency profiles for radiation therapy and 
medical physics, and other quality-focused organizations such as 
the World Health Organization and the Canadian Partnership for 
Quality Radiotherapy. Items that were redundant or beyond 
scope were eliminated by investigator consensus, generating a 
refined list of 105 unique potential competency items. This list 
was subjected to an international two-round modified Delphi 
process with experts in radiation oncology, radiation therapy, 
and medical physics. In the first round, each item was 
individually scored on a 9-point Likert scale to indicate 
agreement that an item should be included in the competency 
profile. Items with a mean score of 7.0-9.0 were included, < 4.0 
were excluded, and 4.0-6.9 were refined and rescored in Round 
2 for inclusion or exclusion in the competency profile following 
a web-conference discussion. Items ranked for inclusion by > 75% 
of Round 2 participants were included in the final competency 
profile. 
Results: Fifteen of the 50 invited experts participated in Round 
1: 10 radiation oncologists, four radiation therapists, and one 
medical physicist from 13 centres in five countries. All 105 items 
were scored in Round 1, resulting in a mean score of 7.0-9.0 for 
80 items, < 4.0 for one item, and 4.0-6.9 for 24 items 
(intermediate group). Certain categories emerged as more 
controversial, for example: change management, equipment 
quality assurance (QA), and human factors. Web conference with 
five of the participants resulted in nine of the 24 intermediate 
group items edited for content and/or clarity. In round 2, 12 
participants rescored all intermediate group items. Ten items 
were ranked for inclusion by > 75% of participants and the 
remaining 14 items excluded. The final 90 enabling competency 
items were organized into thematic groups consisting of 18 key 
competencies under headings adapted from Deming's System of 
Profound Knowledge, specifically: Appreciation for a System 
(Process, Standardization & Benchmarking, Organizational & 
Systems Structure, Accessibility, Risk Management), Knowledge 
of Variation (Incident Management, Patient QA, Equipment QA), 
Theory of Knowledge (Change Management, Outcomes), 
Psychology (Human Factors, Quality Culture), and Safety 
(Radiation Safety, General/Patient Safety). 
Conclusions: This quality and safety competency profile may 
inform minimum training standards for radiation oncology 
residency programs and assist in CanMEDS2015 implementation. 
Other relevant professional groups may benefit from the 
groundwork laid through this process. 
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THE APPLICATION OF HUMAN FACTORS AND SYSTEM ENGINEERING 
IN DETERMINING THE IMPACT OF TECHNOLOGY ON RADIATION 
THERAPY SAFETY 
Brian Liszewski1, Victor Wai Lui2, Lisa Di Prospero1 
1Odette Cancer Centre, Toronto, ON 
2University of Toronto, Toronto, ON 
Purpose: Radiation oncology is an increasingly complex 
discipline. As this complexity grows, however, so too does the 
risk of medical error and patient harm. The interaction of 
practitioners, environment and technology is the focus of human 
